Lixte Biotechnology Holdings Stock Probability Of Bankruptcy
| LIXT Stock | USD 3.35 0.12 3.46% |
Lixte | Probability Of Bankruptcy |
Lixte Biotechnology Holdings Company probability of financial unrest Analysis
Lixte Biotechnology's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Lixte Biotechnology Probability Of Bankruptcy | Over 72% |
Most of Lixte Biotechnology's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Lixte Biotechnology probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Lixte Biotechnology odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Lixte Biotechnology Holdings financial health.
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lixte Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Lixte Biotechnology Holdings has a Probability Of Bankruptcy of 72%. This is 66.32% higher than that of the Biotechnology sector and 31.29% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 80.77% lower than that of the firm.
Lixte Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in probability of bankruptcy category among related companies.
Lixte Biotechnology Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | (0.49) | (0.89) | (0.62) | (1.13) | (1.18) | (1.24) | |
| Net Debt | (2.6M) | (5.1M) | (4.8M) | (5.4M) | (4.2M) | (4.0M) | |
| Total Current Liabilities | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
| Total Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
| Total Current Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.2M | 2.2M | |
| Total Cash From Operating Activities | (1.7M) | (2.1M) | (4.1M) | (4.6M) | (4.3M) | (4.1M) |
Lixte Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.64 | ||||
| Current Valuation | 7.09 M | ||||
| Shares Outstanding | 2.25 M | ||||
| Shares Owned By Insiders | 20.48 % | ||||
| Shares Owned By Institutions | 5.08 % | ||||
| Number Of Shares Shorted | 16.72 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 15.55 X | ||||
| EBITDA | (5.09 M) | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Beta | -0.29 | ||||
| Market Capitalization | 7.79 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
| Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lixte Biotechnology Piotroski F Score and Lixte Biotechnology Altman Z Score analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.